Back to Trials
NCT07566390PHASE1Recruiting

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

Novo Nordisk A/S

Start Date

5/1/2026

Completion Date

11/26/2026

Summary

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

Eligibility Criteria

Age Range: 18 years to 55 years

Inclusion Criteria: 1. Male or female 2. Age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. 4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator. Exclusion Criteria: 1. Known or suspected hypersensitivity to study intervention(s) or related products. 2. Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. 3. Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) \[48 millimole per mole (mmol/mol)\] at screening.

Interventions

DRUG

NNC0113-5840

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ObesityOverweight

Locations

PAREXEL Glendale/LA EPCU

Glendale, California 91206

United States